SCHEMBL5954479

SCHEMBL5954479

CN(C)c1cccc(Oc2ccc(N)cc2)c1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.66
SMN1; SMN2 Q16637 3/20 0.66
MAPT P10636 3/20 0.66
MEN1 O00255 2/20 0.66
KMT2A Q03164 2/20 0.66
MITF O75030 1/20 0.66
GAA P10253 1/20 0.66
GFER P55789 1/20 0.66
NLRP1 Q9C000 1/20 0.66
NOD2 Q9HC29 1/20 0.66
MAOA P21397 1/20 0.53
TDP1 Q9NUW8 3/20 0.50
CYP3A4 P08684 2/20 0.50
TSHR P16473 1/20 0.50
NPC1 O15118 2/20 0.49
RAB9A P51151 2/20 0.49
NLRP3 Q96P20 1/20 0.49
MAOB P27338 1/20 0.48
TEAD4 Q15561 1/20 0.47
MAPK1 P28482 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Acetic Acid SCHEMBL4630383 0.91 MEN1 (0.54) ALDH1A1SMN1; SMN2MAPTMEN1KMT2A
SCHEMBL390876 0.87 ALDH1A1 (0.52) ALDH1A1SMN1; SMN2MAPTMEN1KMT2A
SCHEMBL30085363 0.87 ALDH1A1 (0.52) ALDH1A1SMN1; SMN2MAPTMEN1KMT2A
SCHEMBL5669695 0.85 BCHE (0.53) ALDH1A1SMN1; SMN2TSHRMAOBAPP
SCHEMBL28967632 0.84 NR4A1 (0.59) ALDH1A1SMN1; SMN2MAPTMEN1KMT2A
SCHEMBL30166977 0.84 NR4A1 (0.59) ALDH1A1SMN1; SMN2MAPTMEN1KMT2A
SCHEMBL15474243 0.84 HSD17B1 (0.51) ALDH1A1SMN1; SMN2MAPTMEN1KMT2A
SCHEMBL15472295 0.83 NPBWR1 (0.53) ALDH1A1SMN1; SMN2MAPTMEN1KMT2A
SCHEMBL12260636 0.82 APP (0.44) ALDH1A1SMN1; SMN2MAPTMEN1KMT2A
SCHEMBL17371502 0.81 ALDH1A1 (0.73) ALDH1A1SMN1; SMN2MAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060025589-A1 2-Thiohydantoine derivative compounds and use thereof for the treatment of diabetes LABORATOIRES FOURNIER S.A. (FR) 2006-02-02 US disclosed
EP-1546111-A2 2-THIOHYDANTOINE DERIVATIVE COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF DIABETES LABORATOIRES FOURNIER S.A. (FR) 2005-06-29 EP disclosed
WO-2004031160-A2 2-THIOHYDANTOINE DERIVATIVE COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF DIABETES LABORATOIRES FOURNIER S.A. (FR) 2004-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060025589-A1 2-Thiohydantoine derivative compounds and use thereof for the treatment of diabetes LIPC, CYP4F2, SLC5A2 ALDH1A1 452/4885SMN1; SMN2 4641/4885MAPT 4311/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.